Filana Therapeutics, Inc.FLNA
What Filana Therapeutics, Inc. does.
Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to develop transformative medicines to improve the lives of patients with central nervous system (CNS) disorders, such as Tuberous Sclerosis Complex (TSC)-related epilepsy and other diseases associated with dysregulation or overexpression of filamin A. Our science is based on modulating the activity of a critical protein in the brain for patients with certain CNS disorders, such as TSC. Our lead therapeutic drug candidate, simufilam, was under clinical evaluation for the proposed treatment of Alzheimer’s disease in two Phase 3 clinical studies through 2024, when all ongoing clinical trials for simufilam in Alzheimer’s disease were discontinued. The phase out of the Company’s Alzheimer's disease development program was completed in the second quarter of 2025.
Our lead therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy. Simufilam was discovered and designed in-house and was characterized by our academic collaborators during research activities that were conducted from approximately 2008 to date.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$6.3M | -$32.4M | -$76.2M | -$97.2M | -$24.3M | -$91.0M |
| Free cash flow | — | -$52.4M | -$80.2M | -$82.4M | -$117.0M | -$32.8M |
More on FLNA.
- Filana Therapeutics, Inc. summary
- Filana Therapeutics, Inc. financial statements
- Filana Therapeutics, Inc. key metrics
- Filana Therapeutics, Inc. health scores and style box
- Filana Therapeutics, Inc. earnings
- Filana Therapeutics, Inc. dividends
- Filana Therapeutics, Inc. valuation
- Filana Therapeutics, Inc. ownership and insiders
- Filana Therapeutics, Inc. peers
Figures from Filana Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.